Clareo Health | A Study on the Efficacy of Immunotherapy, the Occurrence and Severity of Adverse Reactions in Patients with Non-small Cell Lung Cancer in High-altitude Areas
A Study on the Efficacy of Immunotherapy, the Occurrence and Severity of Adverse Reactions in Patients with Non-small Cell Lung Cancer in High-altitude Areas
Second Affiliated Hospital of Xi'an Jiaotong University
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
(1) Patients with primary non-small cell lung cancer (adenocarcinoma/squamous cell carcinoma/adenosquamous cell carcinoma/large cell lung cancer/others) with clear cellular/histopathological evidence; (2) Primary non-small cell lung cancer of any stage receiving immunotherapy for the first time; (3) Patients who have undergone at least 2 cycles of immunotherapy during the treatment period and have undergone one efficacy evaluation; (4) Patients with at least one evaluable target lesion (except for those with uncontrolled brain metastases) according to Response Evaluation Criteria for Solid T Tumors (RECIST, version 1.1); (5) Voluntary participation in research and strong willingness to cooperate; (6) has been residing in Qinghai Province since birth; (7) Have been residing in Shaanxi Province since birth; (8) Be at least 18 years old;
You may not be if
1. Patients with unknown histopathological type were excluded;
2. Patients with unclear diagnosis and treatment information and immunotherapy-related adverse reactions;
3. Patients with bipolar/multiple primary non-small cell lung cancer with other tumors were excluded;
4. Patients who are unwilling to join the study and have poor willingness to cooperate;
5. Patients who migrated to Qinghai or Shaanxi from different altitudes and had a history of migration between the two provinces were excluded;
6. exclude patients with a history of emigration from parents;
7. Patients who have received immunotherapy for other tumors in the past;
8. Prior immunosuppressive therapy prior to exclusion
